Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...

That study, based on an older return calculation method that has since been widely replicated, highlighted the strong ...

But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

Pfizer’s recent earnings look solid at first glance, but there’s a quirky twist. A US$7 billion unusual expense dragged down ...

Costs of product revenue were $0.4 million for the quarter ended March 31, 2025, compared to $0.5 million for the quarter ended March 31, 2024, partially due to obsolete inventory write offs of ...

Pfizer has received a “Moderate Buy” consensus from fifteen analysts, signaling cautious optimism rather than fanfare. One ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...